Whitepaper/App Note

Whitepaper: The importance of being profiled: Improving drug candidate safety and efficacy using cross-target profiling

Posted: 11 July 2011 |

Whitepaper: The importance of being profiled: Improving drug candidate safety and efficacy using cross-target profiling

Profiling of putative lead compounds against a representative panel of important enzymes, receptors, ion channels and transporters is an excellent way to establish a preliminary view of potential issues that might later hamper development.

Merck Millipore logoAn early idea of which off-target activities must be minimized can save valuable time and money during the preclinical lead optimization phase if pivotal questions are asked beyond the usual profiling at hERG. The best data for critical evaluation of activity at GPCRs and ion channels is obtained using functional assays, since binding assays cannot detect all interactions and do not provide information on whether the interaction is that of an agonist, antagonist, or allosteric modulator. This overview discusses the benefits of in vitro assays, specific decision points where profiling can be of immediate benefit, and highlights relevant profiling services offered by Merck Millipore.

This whitepaper is restricted - login or subscribe free to access

Issue 6 2018 magazine coverThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • bi-monthly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here

 

Related organisations

Comments are closed.

Send this to a friend